Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Adaptimmune Therapeutics PLC changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 76 | 1 | 81 | +6 |
| Shares | 153.9M | 193.8K | 151.7M | −2.01M (−1.3%) |
| Value | $150.0M | $188.9K | $144.1M | −$5.70M (−3.8%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 283,626 | $269.6K | 0.00% |
| Gsa Capital Partners LLP | 99,662 | $95.0K | 0.01% |
| Two Sigma Investments, LP | 57,201 | $54.4K | 0.00% |
| Palisades Investment Partners, LLC | 43,455 | $41.3K | 0.02% |
| IFG Advisory, LLC | 27,500 | $26.1K | 0.00% |
| Fullcircle Wealth LLC | 35,000 | $25.8K | 0.01% |
| Newman Dignan & Sheerar, Inc. | 27,957 | $20.6K | 0.00% |
| Ballentine Partners, LLC | 16,758 | $15.9K | 0.00% |
| Graham Capital Management, L.P. | 12,592 | $12.0K | 0.00% |
| Greenleaf Trust | 11,856 | $11.3K | 0.00% |
| Signaturefd, LLC | 6,620 | $6.29K | 0.00% |
| Tower Research Capital LLC (TRC) | 4,665 | $4.43K | 0.00% |
| Plante Moran Financial Advisors, LLC | 925 | $879 | 0.00% |
| Bryn Mawr Trust Co | 604 | $574 | 0.00% |
| Northwestern Mutual Wealth Management Co | 69 | $66 | 0.00% |
| TD Waterhouse Canada Inc. | 14 | $13 | 0.00% |
| Danske Bank A/S | 1 | $1 | 0.00% |
| Simplex Trading, LLC | 1,052 | $0 | 0.00% |
Sold out (12)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Baker Bros. Advisors LP | 2,343,695 | $2.28M |
| Tang Capital Management LLC | 1,743,619 | $1.70M |
| Acuitas Investments, LLC | 541,201 | $527.6K |
| Citadel Advisors LLC | 142,891 | $139.3K |
| Marquette Asset Management, LLC | 98,589 | $96.1K |
| Main Street Financial Solutions, LLC | 31,190 | $30.4K |
| JTC Employer Solutions Trusteee Ltd | 26,156 | $26.0K |
| XTX Topco Ltd | 12,399 | $12.1K |
| Raymond James & Associates | 10,218 | $9.96K |
| Wetzel Investment Advisors, Inc. | 6,000 | $9.48K |
| Baader Bank INC | 10,287 | $8.17K |
| National Bank of Canada | 10 | $10 |
Not filed for Q3 2024 yet (1)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 193,757 | $188.9K |